Rituximab News and Research

RSS
Rituximab is approved by the Food and Drug Administration (FDA) to be used alone or with other drugs to treat certain types of B-cell non-Hodgkin lymphoma. It is also approved to be used with methotrexate to treat rheumatoid arthritis. Rituximab is also being studied in the treatment of other types of cancer and other conditions.
Ibrutinib shows promise in CLL/SLL

Ibrutinib shows promise in CLL/SLL

MorphoSys announces updated clinical data on its proprietary drug candidate MOR208

MorphoSys announces updated clinical data on its proprietary drug candidate MOR208

Phase III HELIOS trial results show ibrutinib combination therapy improves outcomes  in CLL/SLL patients

Phase III HELIOS trial results show ibrutinib combination therapy improves outcomes in CLL/SLL patients

Ibrutinib and chemotherapy reduce risk of death in patients with CLL or SLL

Ibrutinib and chemotherapy reduce risk of death in patients with CLL or SLL

UCB sponsoring several presentations on Cimzia for Crohn's disease at DDW 2015

UCB sponsoring several presentations on Cimzia for Crohn's disease at DDW 2015

May issue of Red Journal focuses on role of radiation therapy in current lymphoma treatment

May issue of Red Journal focuses on role of radiation therapy in current lymphoma treatment

Chemotherapy or immunosuppressive treatment may reactivate HBV

Chemotherapy or immunosuppressive treatment may reactivate HBV

Johnson & Johnson announces sales of $18.3 billion for Q4 2014

Johnson & Johnson announces sales of $18.3 billion for Q4 2014

IMBRUVICA-rituximab combination well tolerated in patients with relapsed or refractory MCL

IMBRUVICA-rituximab combination well tolerated in patients with relapsed or refractory MCL

Cornerstone Pharmaceuticals initiates CPI-613 Phase I trial in patients with B-cell NHL

Cornerstone Pharmaceuticals initiates CPI-613 Phase I trial in patients with B-cell NHL

MorphoSys, Xencor announce final results from MOR208 Phase 1/2a trial in patients with CLL/SLL

MorphoSys, Xencor announce final results from MOR208 Phase 1/2a trial in patients with CLL/SLL

Plymouth professor awarded grant to find effective treatment for patients with mantle cell lymphoma

Plymouth professor awarded grant to find effective treatment for patients with mantle cell lymphoma

Infinity and AbbVie enter into global collaboration to develop and commercialize duvelisib

Infinity and AbbVie enter into global collaboration to develop and commercialize duvelisib

Clinical studies to treat unmet medical need post-transplantation

Clinical studies to treat unmet medical need post-transplantation

Halozyme reports revenues of $18.4 million, net loss of $16.3 million for Q2 2014

Halozyme reports revenues of $18.4 million, net loss of $16.3 million for Q2 2014

Blood cancer patients in the UK can now benefit from Roche's MabThera SC

Blood cancer patients in the UK can now benefit from Roche's MabThera SC

Zydelig gets FDA approval for treatment of patients with three types of blood cancers

Zydelig gets FDA approval for treatment of patients with three types of blood cancers

Johnson & Johnson sales increase 9.1% to $19.5 billion in second quarter 2014

Johnson & Johnson sales increase 9.1% to $19.5 billion in second quarter 2014

Study reveals why survival for blood cancer patients still varies between regions within Europe

Study reveals why survival for blood cancer patients still varies between regions within Europe

UCB, Dermira enter into licensing agreement for development, commercialization of Cimzia

UCB, Dermira enter into licensing agreement for development, commercialization of Cimzia